secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277515
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210
--------------------------------------------------------------------------------

- Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.
- Net loss for Q3 2025 was $6.0M, down from $11.9M in Q3 2024.
- R&D expenses decreased 32% to $4.0M; G&A decreased 43% to $2.2M due to cost reductions.
- Planning confirmatory Phase 3 trial of LYR-210 for CRS without nasal polyps following FDA meeting.
- Presented positive ENLIGHTEN 2 Phase 3 results at AAO-HNS meeting in October 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525277515/0001193125-25-277515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525277515/lyra-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer